script.reportAU
Infectious disease

Flucloxacillin

Brand: Flucloxacillin Hospira

PBAC's latest decision on Flucloxacillin: Recommended (2015). Considered for Supply of flucloxacillin 1 g injection in a 10 vial pack to address ongoing shortage of the 5 vial pack size on the Australian market.

PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2015
Submissions
1
2015 → 2015

Eligible population

Patients requiring flucloxacillin 1 g injection (same indication as existing 5 vial pack size)

Therapy area
Infectious disease
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Economic model
Cost-minimisation
ICER note
not-modelled — this is a minor submission for an alternative pack size, not a new formulation or clinical evaluation

Similar precedents

Open on full dashboard →